Title : Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.

Pub. Date : 2013 May 15

PMID : 23640345






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 SUMMARY: Vandetanib is a small-molecule inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and receptor tyrosine kinase signaling pathways, which are involved in the pathogenesis of medullary thyroid cancer (MTC). vandetanib epidermal growth factor receptor Homo sapiens